Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Authors: Karolina Poplawska-Domaszewicz, Lucia Batzu, Cristian Falup-Pecurariu, K. Ray Chaudhuri

Source: Neurology and Therapy, Vol 13, Iss 4, Pp 1055-1068 (2024)

Subject Terms: Parkinson’s disease, Foslevodopa, Subcutaneous, Continuous drug delivery, Early morning off, Neurology. Diseases of the nervous system, RC346-429

File Description: electronic resource

Relation: https://doaj.org/toc/2193-8253; https://doaj.org/toc/2193-6536

Access URL: https://doaj.org/article/edd550052ccd4efdb93128992956c14f

Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit

Authors: Moritz A. Loeffler, Annerose Mengel, Constanze Single, Daniel Weiss, Katharina Feil

Source: Frontiers in Medicine, Vol 11 (2024)

Subject Terms: akinetic crisis, foslevodopa, hydrocephalus, Parkinson, case report, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2024.1446345/full; https://doaj.org/toc/2296-858X

Access URL: https://doaj.org/article/6692f2c2cd784b449020b71272251b6d

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel

Authors: John P. Savaryn, Richard L. Smith, Matthew Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David Wagner

Source: Pharmacology Research & Perspectives, Vol 12, Iss 2, Pp n/a-n/a (2024)

Subject Terms: carbidopa, foslevodopa, foscarbidopa, human, levodopa, metabolite profiling, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2052-1707

Access URL: https://doaj.org/article/905647f03fa242e5850562a33da60601

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Authors: Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung

Source: Neurology and Therapy, Vol 12, Iss 6, Pp 1937-1958 (2023)

Subject Terms: Advanced Parkinson’s disease, Foslevodopa/foscarbidopa, Levodopa/carbidopa prodrugs, Motor fluctuations, Subcutaneous infusion, Neurology. Diseases of the nervous system, RC346-429

File Description: electronic resource

Relation: https://doaj.org/toc/2193-8253; https://doaj.org/toc/2193-6536

Access URL: https://doaj.org/article/3c28527413ce4845845ba7b0a3dbeb25

A patient with Parkinson’s disease whose sleep status improved after the introduction of continuous subcutaneous foslevodopa/foscarbidopa infusion

Authors: Hirotaka Sakuramoto, Hiroaki Fujita, Keitaro Ogaki, Keisuke Suzuki

Source: Clinical Parkinsonism & Related Disorders, Vol 11, Iss , Pp 100292- (2024)

Subject Terms: Parkinson’s disease, Continuous subcutaneous foslevodopa/foscarbidopa infusion, Sleep disturbances, Neurology. Diseases of the nervous system, RC346-429

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S259011252400063X; https://doaj.org/toc/2590-1125

Access URL: https://doaj.org/article/93b3ae6f337c457ca897f9cb36dd6e85

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

Authors: Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, Filip Bergquist, Agnita J.W. Boon, Manon Bouchard, Sarah Bray, Sara Dhanani, Maurizio F. Facheris, Nahome Fisseha, Eric Freire-Alvarez, Robert A. Hauser, Anna Jeong, Jia Jia, Pavnit Kukreja, Michael J. Soileau, Amy M. Spiegel, Saritha Talapala, Arjun Tarakad, Enrique Urrea-Mendoza, Jorge Zamudio, Rajesh Pahwa

Source: Clinical Parkinsonism & Related Disorders, Vol 10, Iss , Pp 100239- (2024)

Subject Terms: Levodopa, Carbidopa, Parkinson’s disease, Motor fluctuations, Subcutaneous infusion, Foslevodopa, Neurology. Diseases of the nervous system, RC346-429

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2590112524000082; https://doaj.org/toc/2590-1125

Access URL: https://doaj.org/article/ee4b4d82effb4c59b7e2610de99a7111

Continuous Subcutaneous Carbidopa/Levodopa Demonstrates Benefits in Parkinson Disease Motor Fluctuations, OFF Time

Authors: By:Marco Meglio

Source: Neurology Times (USA), November 20, 2022 News, 3pp

FDA Issues Second Complete Response Letter for AbbVie's Parkinson's Therapy

Authors: By:Formulary Watch

Source: Formulary Watch (USA), June 25, 2024 News, 2pp

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

Authors: By:Marco Meglio

Source: Neurology Live (USA), January 13, 2024 News, 2pp

AbbVie Announces Launch of 24-Hour Levodopa Infusion in the European Union

Authors: By:Marco Meglio

Source: Neurology Live (USA), January 9, 2024 News, 3pp

Supernus' SPN-830 will face fiercely competitive Parkinson's market if approved by FDA, says GlobalData.

Source: Chemical Business NewsBase (UK), October 13, 2023, 3pp

Parkinson's disease market to exhibit growth at a CAGR of 11.2% during the study period (2019-2032), assesses DelveInsight. [1 table in original article]

Source: Chemical Business NewsBase (UK), May 30, 2023, 3pp

AbbVie provides regulatory update on ABBV-951 (foscarbidopa/foslevodopa) New Drug Application.

Source: Chemical Business NewsBase (UK), March 22, 2023, 2pp

FDA Updates for the Week of March 20, 2023

Authors: By:Denise Myshko

Source: Managed Healthcare Executive (USA), March 25, 2023 News, 4pp

AbbVie Parkinson's drug ABBV-951 faces few hurdles before FDA approval, says GlobalData.

Source: Chemical Business NewsBase (UK), March 23, 2023, 2pp

FDA Wants More Information about AbbVie's Parkinson's Therapy

Authors: By:Formulary Watch

Source: Formulary Watch (USA), March 22, 2023 News, 2pp

AbbVie Submits NDA for Parkinson's Disease

Authors: By:Formulary Watch

Source: Formulary Watch (USA), May 20, 2022 News, 2pp